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Geoffrey S Ginsburg2, Vincent C Henrich5 and Lori A Orlando2,3Abstract
Background: Studies have shown that the quality of family health history (FHH) collection in primary care is
inadequate to assess disease risk. To use FHH for risk assessment, collected data must have adequate detail. To
address this issue, we developed a patient facing FHH assessment tool, MeTree. In this paper we report the content
and quality of the FHH collected using MeTree.
Methods: Design: A hybrid implementation-effectiveness study. Patients were recruited from 2009 to 2012. Setting:
Two community primary care clinics in Greensboro, NC. Participants: All non-adopted adult English speaking patients
with upcoming appointments were invited to participate. Intervention: Education about and collection of FHH with
entry into MeTree. Measures: We report the proportion of pedigrees that were high-quality. High-quality pedigrees are
defined as having all the following criteria: (1) three generations of relatives, (2) relatives’ lineage, (3) relatives’ gender,
(4) an up-to-date FHH, (5) pertinent negatives noted, (6) age of disease onset in affected relatives, and for deceased
relatives, (7) the age and (8) cause of death (Prim Care 31:479–495, 2004.).
Results: Enrollment: 1,184. Participant demographics: age range 18-92 (mean 58.8, SD 11.79), 56% male, and 75%
white. The median pedigree size was 21 (range 8-71) and the FHH entered into MeTree resulted in a database of
27,406 individuals. FHHs collected by MeTree were found to be high quality in 99.8% (N = 1,182/1,184) as compared to
<4% at baseline. An average of 1.9 relatives per pedigree (range 0-50, SD 4.14) had no data reported. For pedigrees
where at least one relative has no data (N = 497/1,184), 4.97 relatives per pedigree (range 1-50, SD 5.44) had no data.
Talking with family members before using MeTree significantly decreased the proportion of relatives with no data
reported (4.98% if you talked to your relative vs. 10.85% if you did not, p-value < 0.001.).
Conclusion: Using MeTree improves the quantity and quality of the FHH data that is collected and talking with
relatives prior to the collection of FHH significantly improves the quantity and quality of the data provided. This allows
more patients to be accurately risk stratified and offered appropriate preventive care guided by their risk level.
Trial number: NCT01372553
Keywords: Family history, Data quality, Patient-centeredBackground
The systematic collection of family health history (FHH)
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stated.of alternative (non-routine) screening procedures (such
as breast MRI) and/or genetic counseling [6-9]. How-
ever, to use FHH for risk assessment, collected FHHs
must have adequate detail. Unfortunately, studies have
shown that the quality of FHH as currently collected in
primary care is inadequate to assess disease risk [10-16].
Existing challenges include lack of patient preparation to
provide FHH [17,18], the amount of time needed to col-
lect FHH [19,20], lack of standardization, and limited
training in synthesizing FHH data into a clinically action-
able care plan [4,18,21,22]. The use of a FHH collection. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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(CDS) may address these challenges and increase the com-
prehensiveness of FHH collection and risk assessment in
primary care [20].
To address these challenges the Genomedical Connec-
tion, a collaboration of Duke University, the University of
North Carolina at Greensboro, and Cone Health, developed
the Genomic Medicine Model with funding from the
Department of Defense. The model [23,24], provides edu-
cation to patients, providers, and community members;
activates patients; and leverages a web-based software
platform, MeTree [25], developed to promote accurate,
high quality patient-entered FHHs for risk assessment
in primary care. MeTree collects information about 48
diseases and provides risk assessment and CDS for five:
breast, ovarian, and colon cancer, thrombophilia, and
hereditary cancer syndromes. CDS documents include a
3 generation pedigree, a tabular FHH for PCPs, and two
separate reports one for patients explaining their risk
level and important points to discuss with their pro-
viders, and one for PCPs that indicates each individual’s
level of risk, what put them at that risk, and what pre-
ventive actions can be taken to manage their risk [25].
This combination of patient education and integration
with primary care is different from other FHH studies
[26,27]. To assess the impact of the Genomic Medicine
Model, MeTree was integrated into two primary care
practices as part of a type II hybrid implementation-
effectiveness controlled clinical trial [28,29]. This paper
describes the content and quality of the FHHs collected
using MeTree.
Methods
Patient recruitment
The protocol for the clinical trial has been previously pub-
lished [23]. In brief, all adult patients scheduled for an up-
coming well visit in two primary care practices were invited
to participate. Only those who were adopted or did not
speak English were excluded. Patients who agreed to par-
ticipate were consented and provided with two brochures,
one about how and why to collect FHH developed in con-
junction with the Genetic Alliance, which included lan-
guage about types of cancers and how to distinguish
primary from secondary tumor sites, and another about
disease risk and prevention. They were also given a work-
sheet with a list of relatives and a list and description of the
conditions collected by MeTree to facilitate data collection
from relatives prior to entering their information into
MeTree. Further information about the development of
these educational materials has been previously published
[24]. A study coordinator was available to assist with ques-
tions. After patient s entered their FHH into MeTree, they
completed a survey regarding who they talked to and what
they learned when collecting their FHH. The study wasapproved by the IRBs of Duke University, University of
North Carolina at Greensboro, Cone Health System,
and the funding agency, the Department of Defense.
FHH data and statistical analyses
FHH pedigree data entered into MeTree was stored in a
SQL database and analyzed using R statistical software
[30]. To define the characteristics and quality of the
entered FHH we used the following criteria defined by
Bennett [31]: (1) three generations of relatives, (2) relatives’
lineage (e.g. paternal or maternal side), (3) relatives’ gender,
(4) an up-to-date FHH, (5) pertinent negatives in FHH
noted (i.e. no FHH of cancer), (6) age of disease onset in af-
fected relatives, and for deceased relatives, (7) the age and
(8) cause of death. The nature of the study meant that all
the FHHs were “up to date”; therefore, we limited analyses
to the remaining 7 criteria. Hence in pedigrees with no de-
ceased relatives we defined 5 possible criteria (excluding
criteria 7 and 8 which related to deceased relatives) and in
those with at least one deceased relative, we defined 7 pos-
sible criteria. For a pedigree to be considered high quality,
at least one individual in the pedigree must meet all quality
criteria (“high quality relative”), similar to previous study
definitions [15]. To understand the impact of MeTree
using broader definitions the percent of pedigrees mee-
ting high quality criteria as a function of the number of
“high quality” relatives is also reported.
Throughout this paper we present data in two ways:
1. Data aggregated by proband (enrolled patient):
counts, proportions and averages for each proband’s
pedigree were calculated and then further analyzed
to show the distribution of counts, proportions and
averages across all pedigrees. Data representing
analysis of a pedigree will be annotated by the term
“pedigree” throughout this paper and data describing
the proportion of relatives meeting specific criteria
will be termed “proportion within pedigree”.
2. Data aggregated by all individuals (enrolled patient
and relatives): In this case, each person represents
a data point, and all counts, proportions and
averages represent the entire group of individuals
without reference to which pedigree he or she
belongs. As an example, for breast cancer
prevalence the number of individuals listed as
having breast cancer in the database was divided
by the total number of individuals in the database.
Data representing analysis of individuals without
reference to the pedigree will be annotated by the
term “individual” and data describing the
proportion of individuals in the database meeting
specific criteria will be termed “prevalence across
individuals” without respect to pedigree
membership.
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pared disease prevalence and heritability within our families
to the general population using relative-type recurrence-
risk ratios (lambdas) [32-34]. Lambdas represent the prob-
ability that a relative (e.g. sibling) will have a disease given
the proband has the disease divided by the probability that
the underlying population (in our case the enrolled patient)
has the disease. We compare lambdas for our population to
previously published population-based lambdas for siblings,
since on average they share 50% of their DNA.
In calculation of quality criteria and disease prevalence,
individuals were only counted once. For example, if a pa-
tient’s aunt had breast cancer and thrombosis, she would
meet quality criterion for age of disease onset if the age of
onset for only one of the diseases was entered. In addition,
when calculating disease prevalence across individuals she
would only be counted once for overall disease prevalence.
But, when looking at individual diseases she would be
counted in both the breast cancer and thrombosis cate-
gories. Numerical outcome variables were analyzed using
multivariate analysis with standard linear regression, and
categorical variables with logistic linear regression. Co-
variates evaluated include: age, gender, ethnicity, educa-
tion level, family size, percent of family with cancer,
proband’s perception of their knowledge of their FHH.
Results
Study enrollment
5,971 patients were contacted for participation in the
study. 4,277 (72%) agreed to participate. However, given
that there was only one designated computer in each
clinic, only one participant per clinic could be enrolled
per hour, thus 1,184 patients were enrolled and entered
their FHH into MeTree. Enrollees were similar to the
underlying clinic population with the exception of slightly
more women and slightly fewer minorities than the gen-
eral clinic population. (Table 1) Median pedigree size was
21 (range 8-71) (Figure 1) with 27,406 individuals entered
in the database.
Talking to relatives
53.89% (N = 638/1184) of patients contacted relatives to
collect FHH. Those who contacted family talked to an
average of 2.89 relatives (SD 1.58). Patients were more
likely to contact family if they were women (57.35% vs.
48.98% of men, p = 0.004) or had more cancer in the
family (15.15% vs. 12.15%, p < 0.001) and women (3.04 vs.
2.62 relatives for men, p < 0.001) and those with larger pedi-
grees (correlation = 0.13, slope = 0.02/relative, p < 0.001)
talked to more relatives. For those who did not talk to their
relatives, the most common reasons were: already knowing
their FHH (N = 252/541, 46.58%), family not being available
(N = 162/541, 29.94%), and having no time (N = 97/541,
17.92%).Perceptions of FHH knowledge
Regarding FHH knowledge the mean score was 4.30
(SD = 1.30) on a Likert scale (with 1 = no knowledge and
7 = knowing nearly everything). Knowledge perception
was positively correlated with percent of pedigree with
cancer (correlation = 0.16, slope = 1.97/percent increase,
p-value < 0.001.) Women also tended to feel they had a
higher knowledge of their FHH (4.46 vs. 4.08 for mean,
p-value < 0.001).
Quality criterion
MeTree ensures the first 4 FHH quality criteria are met:
three generations, relatives’ lineage, relatives’ gender, and
pertinent negatives. No predictors of quality were identi-
fied during multivariate analyses. Table 2 shows data
comparing FHHs meeting each criteria with MeTree to
that found during a chart review of FHH prior to study
start [15]. In all categories except cause of death,
MeTree FHHs met more criteria.
Age of disease onset
The mean proportion within pedigree for reporting age
of disease onset was 8% (range 0.0-40.0%, SD 7.0).
Within the subgroup of pedigrees with at least one rela-
tive with age of disease onset reported (N = 854/1184,
72.13%) it was 10% (range 1.0-40.0%, SD 7.0).
Cause of death
The mean proportion within pedigree for reporting the
cause of death for deceased relatives was 12% (range 0.0-
100%, SD 15.0). Within the subgroup of pedigrees with
at least one relative with cause of death reported (N =
695/1179, 58.95%) it was 21% (range 3.0-100%, SD 15.0).
Age of death
The mean proportion within pedigree for reporting the age
of death on deceased relatives was 88% (range 0.0-100%,
SD 23.0). Within the subgroup of pedigrees with at least
one relative with age of death reported (N = 1156/1179,
98.05%) it was 89% (range 9.0-100%, SD 19.0).
Age and cause of death
The mean proportion within pedigree for reporting both
the age and cause of death on deceased relatives was 6%
(range 0.0-100%, SD 11.0). Within the subgroup of pedi-
grees with at least one relative with age and cause of
death reported (N = 479/1179, 40.62%) it was 16% (range
3.0-100%, SD 11.0).
High quality pedigrees
FHHs collected by MeTree were high quality in 99.83%
(N = 1182/1184) when requiring only one relative to meet
all the quality criteria. Figure 2 shows how the proportion
of high quality FHHs changes as the proportion of
Table 1 Characteristics of patients enrolled to date as compared to the general clinic population*
Study patients (N = 1184) N (%) Baseline clinic population (N = 45000) N (%)
Gender
Male 490 (41.4) 25,245 (56.1)
Female 694 (58.6) 19,215 (42.7)
Ethnicity
White 969 (81.8) 33,840 (75.2)
Black 159 (13.5) 6,975 (15.5)
Other 56 (4.7) 4,230 (9.4)
Age
Mean (SD) 58.8 (11.8) 59.3 (13.5)
<50 250 (21.1) NA
50-65 575 (48.6) NA
>65 359 (30.3) NA
Education
HS or less 158 (13.3) NA
Some college 245 (20.7) NA
College deg 461 (38.9) NA
Any grad 320 (27.0) NA
*previously published [28].
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quality relatives) increases from 0 to 1. Even when 40% of
the pedigree must contain high quality relatives, over 60%
of the FHHS were still high quality.
Relatives with no reported data
Given how MeTree structures FHH collection, it is not
possible to differentiate relatives who are healthy, and
therefore do not have any diseases, from relatives for0
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Figure 1 Mean pedigree size for each participant.whom the patient does not know their medical history.
Since we cannot distinguish, we report the frequency
of having no data reported for any given relative
(“no data”) and for relative categorized by degree of
relatedness to the patient.
For all pedigrees the proportion within pedigree of no
data relatives was 8% (range 0.0-8.6%, SD 1.4) (an aver-
age of 1.9 relatives/pedigree (range 0-50, SD = 4.14)). For
the subgroup of pedigrees with at least one no data rela-
tive (N = 452/1184) the proportion increased to 20%
(range 1.0-50.0%, SD = 5.4) or 4.97 relatives/pedigree
(range 1-50, SD = 5.44). Having a lower proportion
within pedigree of no data relatives was associated with
FHH knowledge (correlation = -0.19, slope = -0.02/point
increase in FHH knowledge, p-value < 0.001) and talking
with family members (4.98% if talked to a relative vs.
10.85% if did not, p-value < 0.001). Talking with family
members also increased the number of pedigrees for
which 100% of relatives had at least some information
entered (70.38% if talked to a relative vs. 51.83% if did
not, p-value < 0.001). Multivariate analyses indicated that
African-Americans (OR = 3.24, CI 1.95-5.41, p-value <
0.001) and older patients (OR = 1.04, CI 1.01-1.06,
p-value < 0.001) were more likely to have relatives with
no data; but having a larger pedigree had no effect.
First degree relatives (FDR)
On average the proportion within pedigree of FDRs with
no data (e.g. parents, siblings, children) was 1% (range
0.0-89%, SD 5.0). However, only 30 pedigrees of the total
Table 2 Number (%) of Pedigrees that meet each quality criteria
FHH* documentation prior to MeTree [15] MeTree
N = 390 for all and 227 for deceased N = 1184 for all and 1179 for deceased
Quality criterion
1. 3 generations of relatives 0 (0%) 1184 (100%)
2. Relatives’ lineage 111 (28.4%) 1184 (100%)
3. Relatives’ gender 356 (91.2%) 1184 (100%)
4. Pertinent negatives noted 173 (44.3%) 1184 (100%)
5. Age of disease onset 71 (18.2%) 854 (72.1%)
6. Cause of death 213 (98.1%) 695 (58.9%)
7. Age of death 172 (75.7%) 1156 (98.0%)
*FHH = family health history.
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subgroup the proportion was much higher at 26% (range
7.0-89%, SD 17.0).Second degree relatives (SDR)
A larger percentage of SDRs (e.g. grandparents, aunts)
had no data, 11% (range 0.0-100%, SD = 21.0). Among
pedigrees with at least one SDR with no data (N = 447/
1184) the mean proportion was 30% (range 2.0-100%,
SD = 25.0). Grandparents were the most likely SDR to
have no data (mean = 16%, range 0.0-1.00, SD = 28.0)
and among pedigrees with at least one grandparent with
no data (N = 345/1184) the proportion increased to 54%
(range 25.0-100%, SD = 25.0).0.00
0.25
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0.00 0.25 0.50 0.75 1.00
Proportion of High Quality Relatives for Pedigree
to be Considered High Quality
P
ro
po
rt
io
n 
of
 P
ed
ig
re
es
 C
on
si
de
re
d 
to
 b
e 
H
ig
h 
Q
ua
lit
y
Figure 2 Percent of high-quality pedigrees as percent of relatives
with high-quality pedigrees required increases.Deceased relatives
The mean proportion within pedigree of deceased relatives
was 46% (range 0.0-95%, SD = 18.0); only 5 pedigrees had
no deceased relatives. Prevalence across individuals for de-
ceased relatives was 44.75% (N = 12,264). Of those who
were deceased, 30% were FDRs and 59% SDRs (of which
42% were grandparents).
Disease proportion and risk recurrence ratios
When looking at probands only, the disease prevalence
rates were: breast cancer 6.48% (N = 45/694), colon cancer
0.42% (N= 5/1184), diabetes 9.29% (N = 110/1184), heart
attack 3.04% (N = 36/1184). This is comparable to age ad-
justed national prevalence rates for: diabetes (9.4%) [35],
heart disease (6.4%) (which includes heart attack as well
as other forms of heart disease) [36], and colon cancer
(0.50%) [37]; though the rate of breast cancer was higher
than the national rate (3.7%) [37]. When looking at
prevalence across individuals the rates were as follows:
ovarian cancer 0.97% (N = 133/13,659 females), breast
cancer 4.71% (N = 644/13,659 females) with an additional
2 men, colon cancer 1.37% (N = 376/27,406), hereditary
cancer syndromes 0.91% (N = 250/27,406), thrombosis
1.76% (N = 482/27,406), “heart attacks” 8.76% (N = 2400/
27,406), diabetes 6.36% (N = 1744/27,406), asthma 2.82%
(N = 744/27,406), and dementia 3.60% (N = 987/27,406).
Sibling recurrence-risk ratios were as follows: breast can-
cer 2.61 (CI 1.29-4.65), colon cancer 27.86 (CI 0-91.22),
heart attack 5.89 (CI 2.44-10.49), and diabetes 2.49 (CI
1.79-3.18), which are similar to reported population values
for: breast cancer (1.8), colon cancer (2.7), ischemic heart
disease (2.0), and diabetes (5.3) [38].
Discussion
MeTree provides a significant improvement in the quality
and content of FHH collection and thereby improves our
ability to perform risk assessment and appropriately iden-
tify individuals meeting criteria for “non-routine” screening
or diagnostic strategies based on current clinical guidelines.
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found improvements in collection of FHH and the ability
to provide risk assessments [26,39,40]. We found that by
educating patients about how and what to collect for FHH,
patients talked with relatives and were able to give more,
higher quality information. Those who talked with their
relatives and those with higher perceptions of their FHH
knowledge were more likely to have data reported on all
family members and have a lower proportion of relatives
with no data entered (no data relatives). As the amount
and the quality of data on each relative improves, the abil-
ity to perform accurate risk assessment is also improved;
and, as shown by the fact that over 60% of MeTree pedi-
grees had at least 40% of relatives meeting all the quality
criteria (Figure 2), it will allow risk assessments to occur at
higher rates than what currently occurs in practice.
To assess the generalizability of our findings, we com-
pared the data to published population values. In particu-
lar, we wanted to evaluate whether those who participated
were more likely to have a disease or have family members
with a disease that would activate them, making them
more likely to report a higher quality FHH than the gen-
eral population. We found that those who participated in
this study had similar disease prevalence for colon cancer
[37] and diabetes [35] but a slightly higher prevalence of
breast cancer [37] as compared to national statistics. They
also had a higher disease prevalence within their families
for colon cancer [41] and breast cancer [41,42]. However,
sibling recurrence-risk ratios, which take into consider-
ation the relationships of affected members within fam-
ilies, were consistent with reported population values
across all diseases [38]. From this we conclude that be-
cause the probands were demographically similar to the
underlying clinic population, to the disease prevalence in
the general U.S. population, and to the sibling risk-ratios
in the general U.S. population, our findings are likely to be
generalizable despite being slightly enriched with probands
with breast cancer. In addition, because few probands had
any of the diseases (even though the percentage for breast
cancer was higher), the effect of a recruitment bias, if
present, is expected to be minimal.
There are some other biases that must be taken into
account in the interpretation of this data. A higher per-
centage of patients’ FHHs collected by primary care pro-
viders (PCP) [15] (as seen in the baseline chart review)
contained cause of death information than those collected
in MeTree. It is highly probable that this is a result of
reporting bias. In the baseline chart review, 71.8% (N =
163/227) of pedigrees had no deceased relatives men-
tioned at all; while with MeTree < 1% (N = 5/1184) had no
deceased relatives. This highlights the difference in the
type of information collected by providers. When pro-
viders do report a deceased relative they almost always re-
port cause of death; however, they only rarely capturedeceased relatives. The source of this bias is likely that
providers tend to be disease focused. If patients do not
know what a family member died of, providers are un-
likely to make note of the death at all. In contrast the en-
tire family structure is known with MeTree, as are all the
relatives who are deceased, even if the cause of death is
not known. Currently, no risk assessment algorithms take
in to consideration a relative’s cause of death; only their
age of death, age of disease onset, and presence of disease
are considered. While this may change in the future and
the collection of this information needs to be improved, it
does not, at the moment, affect ability to assess risk.
Incomplete second degree relative (SDR) data poses
another limitation, as SDR data, and grandparents in
particular, are used in risk assessment calculations, par-
ticularly for colon cancer screening and hereditary cancer
syndrome risk [43]. The Family Healthware Intervention
Trial (FHITr) also found that reporting of “don’t know”
responses was significantly higher for second- versus first-
degree relatives (FDR) for all six diseases assessed [40] at
rates consistent with what we found (1% for FDR vs. 11%
for SDR). We also found that probands who did not know
the health history of one grandparent were much more
likely not to know the others. This was improved signifi-
cantly among those who talked with their relatives (10%
vs. 23%, p-value < 0.001) and suggests that reporting can
be improved by encouraging family discussions. However,
this problem is likely to persist because of ongoing gener-
ational biases against discussing medical problems and the
increasing separation of family units in today’s society.
Conclusion
In conclusion, MeTree provides PCPs with a higher qual-
ity FHH than they are able to collect on their own, by
compensating for the lack of patient preparation and
the time constraints of the clinic visit. The amount of
data entered and the quality of the data were sufficient
to perform risk assessments on the vast majority of pa-
tients, allowing providers to focus on review of FHH
(instead of collection) and risk assessment and interven-
tion plans based on that knowledge—both from their
own knowledge of risk and on the guideline-based rec-
ommendations from MeTree.
Competing interests
All authors declare that they have no competing interest to report.
Authors’ contributions
RW participated in interpretation of data, drafted and critically revised the
manuscript, and gave final approval of the current version. TH analyzed and
assisted in interpretation of the data, assisted in drafting the manuscript, and
gave final approval of the current version. AB contributed to concept and
design of the study, critically revised the manuscript, and gave final approval
of the current version. KP assisted in data acquisition and interpretation,
critically revised the manuscript, and gave final approval of the current
version. EH contributed to analysis and interpretation of the data, critically
revised the manuscript, and gave final approval of the current version. GG
Wu et al. BMC Family Practice 2014, 15:31 Page 7 of 8
http://www.biomedcentral.com/1471-2296/15/31contributed to conception and design of the study, critically revised the
manuscript, and gave final approval of the current version. VH contributed to
conception and design of the study, critically revised the manuscript, and
gave final approval of the current version. LO contributed to study design,
interpretation of data, critically revised the manuscript, and gave final
approval of the current version. RW and LO had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the analysis. All authors have no conflicts of interest to report.Acknowledgements
This study is funded by the DoD. All authors are funded by the study as was
time for manuscript preparation. The funding body provided IRB approval
and ethical oversight of the study but did not have a role in the study
design, data collection, analysis, interpretation, or in the writing of this
manuscript. This material is also the result of work supported with resources
and the use of facilities at the Durham, NC VA medical center by RW.
Author details
1Health Services Research and Development, Department of Veteran Affairs
Medical Center, 411 W. Chapel Hill St., Ste 600, Durham, NC 27701, USA.
2Duke Center for Personalized and Precision Medicine, Institute of Genome
Science & Policy, Duke University, 2111 Ciemas, 101 Science Dr., DUMC Box
3382, Durham, NC 27708, USA. 3Duke Department of Internal Medicine, Duke
University Health System, Durham, NC, USA. 4Duke Cancer Institute, Duke
University Health System, Seeley Mudd Building, 10 Bryan Searle Drive,
DUMC Box 3917, Durham, NC 27710, USA. 5Center for Biotechnology,
Genomics and Health Research, UNC-Greensboro, 3701 Moore Humanities
and Research Administration Building, 1111 Spring Garden Street,
Greensboro, NC 27412, USA. 6CSP Epidemiology Center, Department of
Veteran Affairs Medical Center, 411 W. Chapel Hill St., Ste 700, Durham, NC
27701, USA. 7Center for Human Genetics, DUMC, Duke University, Box 3445,
Durham, NC 27710, USA.
Received: 30 September 2013 Accepted: 5 February 2014
Published: 13 February 2014References
1. Scheuner MT, Wang SJ, Raffel LJ, Larabell SK, Rotter JI: Family history: a
comprehensive genetic risk assessment method for the chronic
conditions of adulthood. Am J Med Genet 1997, 71(3):315–324.
2. Scheuner MT, Whitworth WC, McGruder H, Yoon PW, Khoury MJ: Familial
risk assessment for early-onset coronary heart disease. Genet Med 2006,
8(8):525–531.
3. Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ: Family history
of type 2 diabetes: a population-based screening tool for prevention? Genet
Med 2006, 8(2):102–108.
4. Valdez R, Yoon PW, Liu T, Khoury MJ: Family history and prevalence of
diabetes in the US population: 6-year results from the National Health
and Nutrition Examination Survey (NHANES, 1999 2004). Diabetes care
2007, 30(10):2517–2522.
5. Acheson L: Family history and genetic testing for cancer risk. Am Fam
Physician 2010, 81(8):934–938. author reply 934–938.
6. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C,
Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ,
Group American Cancer Society Colorectal Cancer Advisory, U.S. Multi-Society
Task Force, and Committee American College of Radiology Colon Cancer:
Screening and surveillance for the early detection of colorectal cancer and
adenomatous polyps, 2008: a joint guideline from the American Cancer
Society, the US Multi-Society Task Force on Colorectal Cancer, and the
American College of Radiology.
CA-Cancer J Clin 2008, 58(3):130–160.
7. Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United
States, 2008: a review of current American Cancer Society guidelines
and cancer screening issues. CA-Cancer J Clin 2008, 58(3):161–179.
8. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E,
Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr., Taylor
AJ, Weintraub WS, Wenger NK, Jacobs AK, Guidelines American College of
Cardiology Foundation/American Heart Association Task Force on Practice:
2010 ACCF/AHA guideline for assessment of cardiovascular risk in
asymptomatic adults: a report of the American College of CardiologyFoundation/American Heart Association Task Force on Practice Guidelines.
Circulation 2010, 122(25):e584–e636.
9. American Diabetes A: Standards of medical care in diabetes–2011.
Diabetes Care 2011, 34(Suppl 1):S11–S61.
10. Murff HJ, Byrne D, Syngal S: Cancer risk assessment: quality and impact of
the family history interview. Am J Prev Med 2004, 27(3):239–245.
11. Murff HJ, Greevy RA, Syngal S: The comprehensiveness of family cancer
history assessments in primary care. Community Genet 2007, 10(3):174–180.
12. Hayflick SJ, Eiff MP, Carpenter L, Steinberger J: Primary care physicians’
utilization and perceptions of genetics services. Genet Med 1998, 1(1):13–21.
13. Acton RT, Burst NM, Casebeer L, Ferguson SM, Greene P, Laird BL, Leviton L:
Knowledge, attitudes, and behaviors of Alabama’s primary care
physicians regarding cancer genetics. Acad Med 2000, 75(8):850–852.
14. Summerton N, Garrood PV: The family history in family practice: a
questionnaire study. Fam Pract 1997, 14(4):285–288.
15. Powell KP, Christianson CA, Hahn SE, Dave G, Evans LR, Blanton SH, Hauser ER,
Agbaje AB, Orlando LA, Ginsburg GS, Hinrich VC: Collection of family
health history for assessment of chronic disease risk in primary care.
NCMJ 2013, 74(4):279–286.
16. Christianson CA, Powell KP, Hahn SE, Blanton SH, Bogacik J, Henrich VC: The
use of a family history risk assessment tool in a community health care
setting: views of primary care providers. J Genet Couns 2012, 21(5):652–661.
17. Berg AO, Baird MA, Botkin JR, Driscoll DA, Fishman PA, Guarino PD, Hiatt RA,
Jarvik GP, Millon-Underwood S, Morgan TM, Mulvihill JJ, Pollin TI, Schimmel
SR, Stefanek ME, Vollmer WM, Williams JK: National institutes of health
state-of-the-science conference statement: family history and
improving health. Ann Intern Med 2009, 151(12):872–877.
18. Qureshi N, Wilson B, Santaguida P, Little J, Carroll J, Allanson J, Raina P:
Family history and improving health. Evid Rep Tech Assess 2009, 186:1–135.
19. Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC: Family
history-taking in community family practice: implications for genetic
screening. Genet Med 2000, 2(3):180–185.
20. Powell KP, Christianson C, Hahn SE, Dave G, Evans LR, Blanton SH, Hauser ER,
Agbaje A, Orlando LA, Ginsburg GS, Hinrich VC: Collection of family health
history for chronic diseases in primary care. NCMJ 2013, 74(4):279–286.
21. Gramling R, Nash J, Siren K, Eaton C, Culpepper L: Family physician
self-efficacy with screening for inherited cancer risk. Ann Fam Med
2004, 2(2):130–132.
22. Wilson BJ, Qureshi N, Santaguida P, Little J, Carroll JC, Allanson J, Raina P:
Systematic review: family history in risk assessment for common
diseases. Ann Intern Med 2009, 151(12):878–885.
23. Orlando LA, Hauser ER, Christianson C, Powell KP, Buchanan AH, Chesnut B,
Agbaje AB, Henrich VC, Ginsburg G: Protocol for implementation of family
health history collection and decision support into primary care using a
computerized family health history system. BMC Health Serv Res 2011,
11:264.
24. Orlando LA, Henrich VC, Hauser ER, Wilson C, Ginsburg GS: The genomic
medicine model: an integrated approach to implementation of family
health history in primary care. Pers Med 2013, 10(3):295–306.
25. Orlando LA, Buchanan AH, Hahn SE, Christianson CA, Powell KP, Skinner CS,
Chesnut B, Blach C, Due B, Ginsburg GS, Henrich VC: Development and
validation of a Primary Care-based family health history and decision
support program (MeTree©). NCMJ 2013, 74(4):287–296.
26. Cohn WF, Ropka ME, Pelletier SL, Barrett JR, Kinzie MB, Harrison MB,
Liu Z, Miesfeldt S, Tucker AL, Worrall BB, Gibson J, Mullins IM, Elward KS,
Franko J, Guterbock TM, Knaus WA: Health Heritage(c) a
web-based tool for the collection and assessment of family health
history: initial user experience and analytic validity. Public Health
Genomi 2010, 13(7–8):477–491.
27. Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ: Developing Family
Healthware, a family history screening tool to prevent common chronic
diseases. Preventing Chronic Disease 2009, 6(1):A33.
28. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C: Effectiveness-
implementation hybrid designs: combining elements of clinical
effectiveness and implementation research to enhance public health
impact. Med Care 2012, 50(3):217–226.
29. Brown G: Conceptual models for implementation research. In 2nd Annual
NIH conference on the sciene of dissemination and implementation. Bethesda,
MD: NIH; 2009.
30. R Core Team: R: A language and environment for statistical computing.
Vienna, Austria; 2008.
Wu et al. BMC Family Practice 2014, 15:31 Page 8 of 8
http://www.biomedcentral.com/1471-2296/15/3131. Bennett RL: The family medical history. Prim Care 2004, 31(3):479–495. vii-viii.
32. Risch N: Linkage strategies for genetically complex traits. I. Multilocus
models. Am J Hum Genet 1990, 46(2):222–228.
33. Risch N: Linkage strategies for genetically complex traits. II. The power of
affected relative pairs. Am J Hum Genet 1990, 46(2):229–241.
34. Risch N: Linkage strategies for genetically complex traits. III. The effect of
marker polymorphism on analysis of affected relative pairs. Am J Hum
Genet 1990, 46(2):242–253.
35. Valdez R, Yoon PW, Liu T, Khoury MJ: Family history and prevalence of
diabetes in the U.S. population: the 6-year results from the National
Health and Nutrition Examination Survey (1999–2004). Diabetes Care
2007, 30(10):2517–2522.
36. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM,
Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ,
Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus
GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G,
Paynter NP, Soliman EZ, et al: Heart disease and stroke statistics–2012 update:
a report from the American Heart Association. Circulation 2012, 125(1):e2–e220.
37. Cancer Fast Stats. [http://seer.cancer.gov/faststats/selections.php?#Output]
38. Hemminki K, Li X, Sundquist K, Sundquist J: Familial risks for common
diseases: etiologic clues and guidance to gene identification. Mutat Res
2008, 658(3):247–258.
39. Qureshi N, Carroll JC, Wilson B, Santaguida P, Allanson J, Brouwers M, Raina P:
The current state of cancer family history collection tools in primary care:
a systematic review. Genet Med 2009, 11(7):495–506.
40. O’Neill SM, Rubinstein WS, Wang C, Yoon PW, Acheson LS, Rothrock N,
Starzyk EJ, Beaumont JL, Galliher JM, Ruffin MT 4th, group Family
Healthware Impact Trial: Familial risk for common diseases in primary
care: the Family Healthware Impact Trial. Am J Prev Med 2009,
36(6):506–514.
41. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ: Population-based study
of the prevalence of family history of cancer: implications for cancer
screening and prevention. Genet Med 2006, 8(9):571–575.
42. Collaborative Group on Hormonal Factors in Breast C: Familial breast
cancer: collaborative reanalysis of individual data from 52
epidemiological studies including 58,209 women with breast cancer and
101,986 women without the disease. Lancet 2001, 358(9291):1389–1399.
43. Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM,
Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ,
Lynch PM, Martin EW Jr., Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike
M, Steinbach G, Terdiman JP, Weinberg D, Nccn: NCCN clinical practice
guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc
Netw 2010, 8(1):8–61.
doi:10.1186/1471-2296-15-31
Cite this article as: Wu et al.: Quality of family history collection with
use of a patient facing family history assessment tool. BMC Family
Practice 2014 15:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
